PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Recruiting
Phase 2
Phase 3
Interventional Study
Prostate Cancer (Adenocarcinoma)
Prostate Brachytherapy
Stereotactic Body Radiation Therapy (SBRT)
Dose Escalation: Solid Tumors
Localized Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,000 (estimated)
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
PRO-BOOST-LC is a prospective, multicenter, randomized phase II/III clinical trial for men with localized or locally advanced prostate cancer without lymph node or distant metastases, confirmed using prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT).
Radiotherapy is an established curative treatment option for prostate cancer. Several modern radioth…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male patients aged ≥18 years.
* Histologically confirmed adenocarcinoma of the prostate.
* Localized or locally advanced prostate cancer classified as cT1-4, cN0, cM0.
* Negative pelvic nodal and distant metastatic disease on baseline PSMA PET.
* NCCN favourbale or unfavourbal…
Contacts